|
1
|
Stillwell TJ, Zincke H, Gaffey TA and
Woods JE: Malignant melanoma of the penis. J Urol. 140:72–75. 1988.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Brady KL, Mercurio MG and Brown MD:
Malignant tumors of the penis. Dermatol Surg. 39:527–547. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tallerman A: Malignant melanoma of the
penis. Urol Int. 27:66–80. 1972. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rogers RS III and Gibson LE: Mucosal,
genital, and unusual clinical variants of melanoma. Mayo Clin Proc.
72:362–366. 1997. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hankins CL, Kotwal S, Majumder S, Weston
P, Phipps A and Anathhanam AJ: Multifocal melanoma of the glans
penis. Plast Reconstr Surg. 118:33e–38e. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jemal A, Saraiya M, Patel P, Cherala SS,
Barnholtz-Sloan J, Kim J, Wiggins CL and Wingo PA: Recent trends in
cutaneous melanoma incidence and death rates in the United States,
1992–2006. J Am Acad Dermatol. 65 5 Suppl 1:S17–S25.e1-3. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
van Geel AN, den Bakker MA, Kirkels W,
Horenblas S, Kroon BB, de Wilt JH, Eggermont AM, Mooi WJ and van
der Aa MN: Prognosis of primary mucosal penile melanoma: A series
of 19 Dutch patients and 47 patients from the literature. Urology.
70:143–147. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Balch CM, Gershenwald JE, Soong SJ,
Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG,
Ding S, et al: Final version of 2009 AJCC melanoma staging and
classification. J Clin Oncol. 27:6199–6206. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ortega FT, Kondo RN, Belinetti FM, Okamura
MO and Tuma B: Primary cutaneous amelanotic melanoma and
gastrointestinal stromal tumor in synchronous evolution. An Bras
Dermatol. 92:707–710. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kibbi N, Kluger H and Choi JN: Melanoma:
Clinical presentations. Cancer Treat Res. 167:107–129. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
De Giorgi V, Grazzini M, Massi D, Rossari
S, Gori A, Janowska A, Bruscino N and Lotti T: Melanoma of the
penis: A clinical dermoscopic case study. Acta Derm Venereol.
90:87–88. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Manivel JC and Fraley EE: Malignant
melanoma of the penis and male urethra: 4 case reports and
literature review. J Urol. 139:813–816. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bracken RB and Diokno AC: Melanoma of the
penis and the urethra: 2 case reports and review of the literature.
J Urol. 111:198–200. 1974. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fenn NJ, Johnson RC, Sharma AK, Attanoos
RL and Horgan K: Malignant melanoma of the penis. Eur J Surg Oncol.
22:548–549. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hayes AJ, Maynard L, Coombes G,
Newton-Bishop J, Timmons M, Cook M, Theaker J, Bliss JM, Thomas JM;
UK Melanoma Study Group, ; et al: Wide versus narrow excision
margins for high-risk, primary cutaneous melanomas: Long-term
follow-up of survival in a randomised trial. Lancet Oncol.
17:184–192. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
>Thomas JM, Newton-Bishop J, A'Hern R,
Coombes G, Timmons M, Evans J, Cook M, Theaker J, Fallowfield M,
O'Neill T, et al: Excision margins in high-risk malignant melanoma.
N Engl J Med. 350:757–766. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
>Cascinelli N, Morabito A, Santinami M,
MacKie RM and Belli F: Immediate or delayed dissection of regional
nodes in patients with melanoma of the trunk: A randomised trial.
WHO melanoma programme. Lancet. 351:793–796. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
>Han D, Zager JS, Shyr Y, Chen H, Berry
LD, Iyengar S, Djulbegovic M, Weber JL, Marzban SS, Sondak VK, et
al: Clinicopathologic predictors of sentinel lymph node metastasis
in thin melanoma. J Clin Oncol. 31:4387–4393. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
>Leijte JA, Kroon BK, Valdés Olmos RA,
Nieweg OE and Horenblas S: Reliability and safety of current
dynamic sentinel node biopsy for penile carcinoma. Eur Urol.
52:170–177. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Reintgen D and Saba H: Chemotherapy for
stage 4 melanoma: A three-year experience with cisplatin, DTIC,
BCNU, and tamoxifen. Semin Surg Oncol. 9:251–255. 1993.PubMed/NCBI
|
|
22
|
Li Y, Yuan H, Wang A, Zhang Z, Wu J and
Wei Q: Malignant melanoma of the penis and urethra: One case
report. World J Surg Oncol. 12:3402014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kirkwood JM, Ibrahim JG, Sondak VK,
Richards J, Flaherty LE, Ernstoff MS, Smith TJ, Rao U, Steele M and
Blum RH: High- and low-dose interferon alfa-2b in high-risk
melanoma: First analysis of intergroup trial E1690/S9111/C9190. J
Clin Oncol. 18:2444–2458. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kirkwood JM, Ibrahim JG, Sosman JA, Sondak
VK, Agarwala SS, Ernstoff MS and Rao U: High-dose interferon
alfa-2b significantly prolongs relapse-free and overall survival
compared with the GM2-KLH/QS-21 vaccine in patients with resected
stage IIB-III melanoma: Results of intergroup trial
E1694/S9512/C509801. J Clin Oncol. 19:2370–2380. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Eggermont AM, Chiarion-Sileni V, Grob JJ,
Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA,
Richards JM, et al: Adjuvant ipilimumab versus placebo after
complete resection of high-risk stage III melanoma (EORTC 18071): A
randomised, double-blind, phase 3 trial. Lancet Oncol. 16:522–530.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Henderson MA, Burmeister BH, Ainslie J,
Fisher R, Di Iulio J, Smithers BM, Hong A, Shannon K, Scolyer RA,
Carruthers S, et al: Adjuvant lymph-node field radiotherapy versus
observation only in patients with melanoma at high risk of further
lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG
02.01): 6-year follow-up of a phase 3, randomised controlled trial.
Lancet Oncol. 16:1049–1060. 2015. View Article : Google Scholar : PubMed/NCBI
|
